OFD1 and breast carcinoma: We have further validated the cell growth defects upon OFD1 inhibition in five cancer cell lines, including colon cancer (HT-29), lung cancer (A549), pancreatic cancer (PANC1), breast cancer (MDA-MB-231), and renal cancer (ACHN) (Fig. 6a–c).